ClearPoint Neuro Inc. (CLPT)

NASDAQ: CLPT · IEX Real-Time Price · USD
9.50
-0.25 (-2.56%)
Dec 5, 2022 3:25 PM EST - Market open
-2.56%
Market Cap 239.41M
Revenue (ttm) 19.66M
Net Income (ttm) -16.20M
Shares Out 24.50M
EPS (ttm) -0.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 43,368
Open 9.69
Previous Close 9.75
Day's Range 9.15 - 9.79
52-Week Range 7 - 16.96
Beta 1.11
Analysts Buy
Price Target 20.66 (+117.5%)
Earnings Date Nov 8, 2022

About CLPT

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration a... [Read more]

Industry Health Care Equipment & Supplies
Founded 1998
Employees 80
Stock Exchange NASDAQ
Ticker Symbol CLPT
Full Company Profile

Financial Performance

In 2021, CLPT's revenue was $16.30 million, an increase of 27.05% compared to the previous year's $12.83 million. Losses were -$14.41 million, 112.5% more than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for CLPT stock is "Buy." The 12-month stock price forecast is 20.66, which is an increase of 117.47% from the latest price.

Price Target
$20.66
(117.47% upside)
Analyst Consensus: Buy
Stock Forecasts

News

ClearPoint Neuro to Present at Upcoming Investor Conferences

SOLANA BEACH, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, ...

3 weeks ago - GlobeNewsWire

ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Misses Revenue Estimates

ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of 21.05% and 6.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

ClearPoint Neuro Reports Third Quarter 2022 Results

Company Reaffirms 2022 Revenue Forecast Company Reaffirms 2022 Revenue Forecast

3 weeks ago - GlobeNewsWire

ClearPoint Neuro Announces FDA Clearance for ClearPoint Prism™ Neuro Laser Therapy System

SOLANA BEACH, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain,...

2 months ago - GlobeNewsWire

ClearPoint Neuro Announces Appointment of Mazin Sabra as Chief Operating Officer

SOLANA BEACH, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain,...

2 months ago - GlobeNewsWire

ClearPoint Neuro Announces FDA Clearance for Software Version 2.1

SOLANA BEACH, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain,...

2 months ago - GlobeNewsWire

2 Stocks Under $20 to Watch

Here are two interesting companies under $20.

Other symbols: CPNG
2 months ago - The Dog of Wall Street

ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Tops Revenue Estimates

ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of 0% and 0.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

ClearPoint Neuro Reports Second Quarter 2022 Results

Record Quarterly Revenue Achieved; Company Reaffirms 2022 Revenue Forecast Record Quarterly Revenue Achieved; Company Reaffirms 2022 Revenue Forecast

3 months ago - GlobeNewsWire

ClearPoint Neuro Congratulates Partner PTC Therapeutics on Being Granted Marketing Authorization by the European Comm...

First Gene Therapy Approved for Direct Infusion into the Brain will be Administered with ClearPoint's SmartFlow® Neuro Cannula First Gene Therapy Approved for Direct Infusion into the Brain will be Admi...

4 months ago - GlobeNewsWire

ClearPoint Neuro Congratulates Neurona Therapeutics on Dosing of Initial Subject in First Clinical Trial of Regenerat...

SOLANA BEACH, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain t...

5 months ago - GlobeNewsWire

ClearPoint Neuro, Inc. (CLPT) Surges 7.6%: Is This an Indication of Further Gains?

ClearPoint Neuro, Inc. (CLPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the n...

5 months ago - Zacks Investment Research

ClearPoint Neuro Congratulates Partner PTC Therapeutics on Receiving Positive CHMP Opinion for Gene Therapy to Treat ...

First Gene Therapy Directly Infused into the Brain to be Administered with ClearPoint's SmartFlow® Cannula First Gene Therapy Directly Infused into the Brain to be Administered with ClearPoint's SmartFl...

6 months ago - GlobeNewsWire

ClearPoint Neuro to Present Investigational Research and Exhibit at the American Society of Gene & Cell Therapy Annua...

SOLANA BEACH, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, t...

6 months ago - GlobeNewsWire

ClearPoint Neuro Reports First Quarter 2022 Results

SOLANA BEACH, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, t...

6 months ago - GlobeNewsWire

ClearPoint Neuro Announces FDA Clearance of the SmartFrame Array™ Version 1.1

Next Generation Neuro Navigation System Designed for Use in Both the MRI Suite and Operating Room Next Generation Neuro Navigation System Designed for Use in Both the MRI Suite and Operating Room

7 months ago - GlobeNewsWire

ClearPoint Neuro to Announce First Quarter 2022 Results May 11, 2022

SOLANA BEACH, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain,...

7 months ago - GlobeNewsWire

ClearPoint Neuro to Present at the B. Riley Securities Disruptive Biotech Enabling Technologies Mini Conference

SOLANA BEACH, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain,...

8 months ago - GlobeNewsWire

ClearPoint Neuro Reports Fourth Quarter and Full-Year 2021 Results

Company Reports Record Revenues Company Reports Record Revenues

9 months ago - GlobeNewsWire

ClearPoint Neuro Reports Fourth Quarter and Full Year 2021 Preliminary Revenue Results and Guidance for Full Year 202...

Company to Hold Earnings Call on March 1, 2022 Company to Hold Earnings Call on March 1, 2022

9 months ago - GlobeNewsWire

ClearPoint Neuro to Participate at the H.C. Wainwright BIOCONNECT Virtual Conference

SOLANA BEACH, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, ...

10 months ago - GlobeNewsWire

ClearPoint Neuro Congratulates Blackrock Neurotech on Receiving Breakthrough Device Designation from the FDA for the ...

SOLANA BEACH, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, ...

1 year ago - GlobeNewsWire

ClearPoint Neuro Reports Third Quarter 2021 Results

Record Revenue Achieved; Company Reaffirms 2021 Revenue Forecast Record Revenue Achieved; Company Reaffirms 2021 Revenue Forecast

1 year ago - GlobeNewsWire

ClearPoint Neuro Congratulates Neurona Therapeutics on IND Clearance for Neural Cell Therapy NRTX-1001 in Chronic Foc...

SOLANA BEACH, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, ...

1 year ago - GlobeNewsWire

Internationally Renowned Neurosurgeon and Accomplished Researcher Dr. Linda M. Liau Joins ClearPoint Neuro Board of D...

SOLANA BEACH, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, ...

1 year ago - GlobeNewsWire